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Article Information  ABSTRACT 
Received: 18th Jan 2017  Bleomycin is an anti-neoplastic drug that has recently been used for the treatment of vascular 
anomalies. An expedient method was developed for the determination of plasma bleomycin 
levels using ion-paired reversed phase high performance liquid chromatography (HPLC). The 
concentration was found to be proportional to the area and the response of the detector was 
determined to be linear over the range of 1-6 µg/ml for both Bleomycin A1 and Bleomycin B2. 
Recovery was approximately 100%. This method provides a simple and rapid way of 
determining the levels of bleomycin A2 and B2 in human and rat plasma 
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INTRODUCTION 
Bleomycins are a mixture of glycopeptide antibiotics isolated 
from the fermentation broth of Streptomycesverticillus. These 
antibiotics are effective against a variety of human neoplasms, 
particularly squamous-cell carcinoma, lymphoma and testicular 
carcinoma. More recently, intralesional bleomycin (IB) has 
been used successfully to treat vascular anomalies. Due to its 
efficacy and apparent lack of side-effects, the drug has 
prompted much clinical research into making it the drug of 
choice for vascular anomalies. Although pulmonary toxicity, 
the major side-effect of this drug which manifests as 
pulmonary fibrosis, has been well established in cancer 
patients, this toxicity in patients after direct injection of 
bleomycin into the lesions has not been studied. The 
monitoring of bleomycin levels in body fluids following such 
intralesional therapy is imperative to determine spill-over 
levels and for the establishment of safety of use [1 – 3]. 
 
Various analytical methods have been developed to assay 
bleomycin fractions in biological fluids. Broughton and Strong 
in 1976 used a radioimmunoassay method to assay this 
compound in phosphate buffered saline (PBS) and in serum. 
This radioimmunoassay method was inadequate as it did not 
distinguish between the various components of the bleomycin 
mixture. Bleomycins are a mixture of active fractions (A1-A6; 
B1-B5) and the pharmacology of the different composite 
fractions are clinically important. Indeed, clinically 
administered bleomycin (Bleomycin Sulphate USP) consists 
55-70%w/w of bleomycin A1 (25-32%w/w of bleomycin B2) 
and the remaining percentage divided among the other sub-
fractions [4 – 6].  
 
In 1980 Shiu and Goehl published a high performance liquid 
chromatography (HPLC) method for the specific determination 
of one of the major component of the bleomycin mixture, 
namely bleomycin A1, in plasma [7]. Ten years later another 
group developed a more sensitive HPLC method using a 
fluorescence detector in a linear gradient, ion-paired reversed 
phase procedure to assay bleomycin A1 in human plasma and 
rat hepatocytes [8].  
 
These HPLC methods for the determination of BLM in plasma 
were validated for the A2 fraction only. Furthermore, these 
long assay methods would not be optimally applicable for 
monitoring a large number of patients’ plasma samples. In the 
present study, a simple, rapid and sensitive method for the 
separation and quantitation of both major fractions, bleomycins 
A1 and B2 in human plasma is reported [9, 10]. 
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MATERIALS AND METHODS 
Analytical procedure 
The analytical method for the determination of Bleomycin 
Sulphate in human and rat plasma using internal standard was 
developed and validated. Sample preparation process was 
performed solid phase extraction technique. The processed 
samples were chromotographed on DISCOVERY C18100A 
(250 x 4.6 mm) column, using Methonal: Buffer-1(80:20, v/v) 
as mobile phase [11]. 
 
Experimental animals 
Experiments were carried out on Wistar rats of either sex 
weighing 150-180gm. They were procured from authorized 
dealer. The animals were housed in polypropylene cages. 
Paddy husk was provided as bedding material, which was 
changed every day. The cages were maintained clean and 
hygienic. They were fed with standard pellet diet and water. 
They were kept in a well-aerated room and a 12-hour light and 
dark cycle was maintained. The room temperature was 
maintained at 22- 240C. The experiments were conducted in 
noise free environment between 9:00 AM to 2:00 PM. All 
procedures were approved and carried out as per the guidelines 
of Committee for the purpose of control and supervision of 
experimental animals (CPCSEA). Prior approval from 
Institutional Animal Ethics Committee (IAEC) was obtained 
for conduction of experiments. {CPCSEA Approval No.: 
RIP/IAEC/2014-15/05}. 
  
Experimental Design 
Procedure: 
Healthy Wistar rat weighing about150- 180gms (either sex), 
kept under room temperature with standard diet and water add 
libitum. Rat dose was calculated according to BSA or body 
weight. The rats were divided into 2 groups of 6 animals each.  
Grouping 
 Group I Test group–Market Formulation (Suspension form 
bleomycin (15 unit i.p) 
 Group II Standard group–Pure drug  (Bleocip-15 unit- i.p ) 
 
Analysis of Bleomycin in Plasma Samples: 
Blood Sample was collected in tube containing 
EDTA/Heparinised micro centrifuge, so as to prevent blood 
coagulation. The blood was centrifuged at 5000 RPM for 20 
min, the plasma will be separated and stored at 2-8°C until 
further analysis of sample by HPLC. Different Pharmacokinetic 
parameter such as Cmax, Tmax, AUC, AUC0-24, AUC0-∞, 
t1/2 will be determined by using statistical analysis. 
 
TABLE 1: EXPERIMENTAL CONDITIONS 
Analyte Bleomycin sulphate 
Biological matrix Plasma 
Retention time 37.618-46.512 
Mobile Phase Pentane sulphonic acid sodium buffer          
(pH-4.3): methanol in gradient elution 
Absorption maxima 254 nm 
Flow rate 1.2 ml/min. 
Injection volume 20 μl 
Column temperature 25 °C 
Column Discovery C18 100A (250x4.6mm) 
Parameters Results 
Analytical range 1-6 µg/ml 
Bleomycin A1 
LOD 0.92μg/ml 
LOQ 2.81μg/ml 
Bleomycin B2 
LOD 5.6µg/ml 
LOQ 17.06 µg/ml5 
 
RESULT 
HPLC Chromatogram of Bleomycin A1 and Bleomycin B2: 
HPLC analysis of mixture of Bleomycin A1 and Bleomycin B2 
chromatogram was optimized in which Retention time of both 
drug was given in Fig. 1 
 
Fig: 1 Chromatogram of Bleomycin sulphate pure drug (6 
μg/ml) 
 
Method development: The bio-analytical method developed is 
simple and shows good accuracy, specificity and reproducible. 
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Formulation Table: 2  Pharmacokinetic Parameters of Bleomycinsulphate 
Pure drug solution Formulation 
Pharmacokinetic 
parameters 
Bleomycin A1 Bleomycin B2 Bleomycin A1 Bleomycin B2 
Tmax(hr) 0.2 0.31 1.31 1.39 
Cmax(μg/ml) 33.15803182 10.13416537 19.24375 87.77291 
t1/2  (hr) 3.12 3.56 6.81 7.23 
AUC (hr/μg/ml) 2.04303346 0.736983229 19.24375 87.77291 
Relative bioavailability - - 9.419205 119.0975677 
 
 
Fig: 2 Chromatogram of Bleomycin sulphate Formulation drug 
 
Fig: 3 Plasma drug concentration curves of Bleomycin solution and Bleomycin 
 
Table: 3 Chromatographic conditions: 
Mobile Phase Pentane sulphonic acid sodium buffer          
(pH-4.3): methanol in gradient elution 
Absorption maxima 254 nm 
Flow rate 1.2 ml/min. 
Injection volume 20 μl 
Column temperature 25 °C 
Linearity: The correlation coefficient (r) obtained was 
calculated and it was found to be greater than 0.99 for 
Bleomycin A1 and Bleomycin B2 given, which is well within 
the acceptance criteria. The concentration was found to be 
proportional to the area and the response of the detector was 
determined to be linear over the range of 1-6 µg/ml for both 
BleomycinA1 and Bleomycin B2. 
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Accuracy: The results indicate that the recoveries are well 
within the acceptance range of 80 – 120%, therefore, method is 
accurate and it can be used for the simultaneous estimation of 
Bleomycin A1 and Bleomycin B2. 
 
Precision: It is a measure of degree of repeatability of an 
analytical method under normal operation and it is normally 
expressed as % of relative standard deviation (% RSD). The 
standard solution was injected for five times and measured the 
area for all five injections in HPLC. The %RSD for the area of 
six replicate injections was found to be within the specified 
limits. Similarly % RSD for Inter day Precision and Intraday 
Precision was given below that was found to be within the 
specified limits. The percentage RSD values for Area and 
Retention Time in precision study were calculated. 
 
LOD and LOQ: The Limit of detection and limit of 
quantification of the method were calculated basing on 
standard deviation of the response and the slope (s) of the 
calibration curve at approximate levels of the limit of detection 
and limit of quantification. The data were represented in 
Table13. The results obtained were within the limit.  
 
Ruggedness: The Ruggedness of the method was found out by 
testing the effect of small deliberate changes in the analyst. The 
method was found to be robust enough that the peak area was 
not apparently affected by small variation in the 
chromatographic conditions. The system suitability parameters 
were within the limits. 
 
Pharmacokinetic and statistical analysis: Standard 
pharmacokinetic parameters obtained from each of the 
individual rat plasma concentration-time profiles of Bleomycin 
sulphate were calculated by non-compartmental methods using 
the computer program WinNonlin. The values of Cmax and Tmax 
were read directly from the arithmetic plot of time versus 
serum concentration of Bleomycin sulphate. The relative oral 
bioavailability of the different formulations has been evaluated 
by the equation: 
Relative bioavailability =
AUC of belomycin pure drug solution
AUC of belomycin formulation solution
 
DISCUSSION 
A HPLC method for the estimation of Bleomycin sulphate in 
human and rat plasma was  developed and validated. Sample 
preparation process was accomplished by solid phase 
extraction. The reconstituted samples were subjected to auto 
injector on a DISCOVER C18, 20 μl at 25 °C using a mobile 
phase consisting of methonal: Buffer-1(80:20,v/v). Transfer 
0.96 g of sodium l-pentanesulphonate to a 1000-ml volumetric 
flask, add 1.86 g of disodium edetate and 5.0 ml of glacial 
acetic acid in 900 volumes of water and then Adjust the volume 
with water up to 1000 ml Mix well and adjust the pH to 4.3 
filter through membrane filter with pore size 0.45 μm and 
degas before use. The method was subjected to complete 
validation and all the validation parameters showed results 
which were within the acceptance limits. A linear response was  
obtained between concentration and peak area ratio of the drug 
in  human and rat plasma.The concentration was found to be 
proportional to the area and the response of the detector was 
determined to be linear over the range of 1-6 µg/ml for both 
Bleomycin A1  and Bleomycin B2 for Bleomycin sulphate. The 
accuracy and precision of  the  method was evaluated by peak 
area ratio response of the drug and internal standard. 
 
CONCLUSION 
The analytical method described is valid for the determination 
of bleomycin in human and rat plasma. The analytical method 
for the determination of  Bleomycin Sulphate in human plasma 
and rat plasma using as internal standard was developed and 
validated. The concentration was found to be proportional to 
the area and the response of the detector was determined to be 
linear over the range of 1-6 µg/ml for both Bleomycin A1 and 
Bleomycin B2.Sample preparation process was performed on 
solid phase extraction technique. The processed samples were 
chromotographed on DISCOVERY C18,using Methonal: 
Buffer-1(80:20,v/v) as mobile phase. 
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